IP Library Granted Patent US 7,700,551
Granted Patent B2
US 7,700,551 · App. 12/215,218 · Granted Apr 20, 2010

Hydrolysable polymeric FMOC-linker

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,700,551
App. No.
12/215,218
Granted
Apr 20, 2010
Kind
B2
Abstract

The invention relates to Fmoc (9-fluorenyl-methoxycarbonyl)-based polymeric conjugates. These conjugates are useful for extending the in-vivo circulation of protein and peptide drugs.

Claims (25)

1. A compound of the formula 1

wherein Z a leaving group and at least one of position 1, 2, 3, 4, 5, 6, 7 or 8 is bound to radical Y;

Y is a radical containing a semi-synthetic carbohydrate biopolymer, which is bound to a N-succinimidyl moiety;

at least one of an available position 1, 2, 3, 4, 5, 6, 7 or 8 is optionally bound to radical X;

X is —SO 3 —R 3 ;

R 3 is independently selected from the group consisting of hydrogen, (C 1 -C 8 )-alkyl and (C 1 -C 8 )-alkyl-R 4 ; and

R 4 is a polymer.

2. The compound according to claim 1 , wherein Z is an N-succinimidyl ester;

Y is:

POLYMER is a semi-synthetic carbohydrate biopolymer;

R 1 is at each occurrence independently a (C 1 -C 8 )-alkyl;

R 2 is independently selected from the group consisting of —C(O)NR—, —C(O)NR(C 1 -C 8 )-alkyl-NR—, —NRC(O)— and —NRC(O)-(C 1 -C 8 )-alkyl-NR; and

R is independently either hydrogen or (C 1 -C 8 )-alkyl.

3. The compound according to claim 2 , wherein R 2 is either —C(O)NR— or —NRC(O)— and wherein R is independently either hydrogen or (C 1 -C 8 )-alkyl.

4. The compound according to claim 3 , wherein said POLYMER is bound via a thioether linkage.

5. The compound according to claim 1 , wherein said semi-synthetic carbohydrate biopolymer is a polysaccharide.

6. The compound according to claim 5 , wherein said polysaccharide is polysialic acid (PSA).

7. The compound according to claim 5 , wherein said polysaccharide comprises at least 3 units of a monosaccharide.

8. A compound according to claim 1 , wherein said compound is selected from the group consisting of I, II, III, IV, V, VI, VII, VIII, IX, X and XI:

9. A conjugate comprising a compound of formula 1 and a protein or peptide drug, the compound of formula 1 having a structure

wherein Z a leaving group and at least one of position 1, 2, 3, 4, 5, 6, 7 or 8 is bound to radical Y;

Y is a radical containing a semi-synthetic carbohydrate biopolymer, which is bound to a N-succinimidyl moiety;

at least one of an available position 1, 2, 3, 4, 5, 6, 7 or 8 is optionally bound to radical X;

R 3 is independently selected from the group consisting of hydrogen, (C 1 -C 8 )-alkyl and (C 1 -C 8 )-alkyl-R 4 ; and

R 4 is a polymer.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2021
From: BAXALTA GMBH; BAXALTA INCORPORATED
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 055189/0005 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER HEALTHCARE SA
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036362/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER INTERNATIONAL INC.
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036374/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 15, 2008
From: TURECEK, PETER, MR.; SIEKMANN, JUERGEN, MR.
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE S.A.
Reel/Frame 021528/0992 →